BEAM THERAPEUTICS INC (BEAM) Stock Analyst Ratings
USA - NASDAQ:BEAM - US07373V1052 - Common Stock
21.87 USD
-0.61 (-2.71%)
22.01 USD
+0.14 (+0.64%)
ChartMill assigns a Buy % Consensus number of 86% to BEAM. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 46.63. This target is 113.21% above the current price.
BEAM was analyzed by 22 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about BEAM.
In the previous month the buy percentage consensus was at a similar level.
BEAM was analyzed by 22 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-06 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-07 | Guggenheim | Maintains | Buy -> Buy |
| 2025-05-07 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-07 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-04-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-28 | B of A Securities | Upgrade | Neutral -> Buy |
| 2025-03-12 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-03-10 | Jones Trading | Upgrade | Hold -> Buy |
| 2025-03-10 | ScotiaBank | Upgrade | Sector Perform -> Sector Outperform |
| 2025-03-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-03 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2025-02-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-27 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-02-26 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-02-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-29 | Cantor Fitzgerald | Upgrade | Neutral -> Overweight |
| 2024-12-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-06 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2024-11-06 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-10-16 | ScotiaBank | Initiate | Sector Perform |
| 2024-09-19 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-09-17 | Jones Trading | Initiate | Hold |
| 2024-09-11 | Stifel | Maintains | Buy -> Buy |
| 2024-08-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-07 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-08-07 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2024-08-07 | JP Morgan | Maintains | Overweight -> Overweight |
BEAM THERAPEUTICS INC / BEAM FAQ
What is the average price target for BEAM THERAPEUTICS INC (BEAM) stock?
22 analysts have analysed BEAM and the average price target is 46.63 USD. This implies a price increase of 113.21% is expected in the next year compared to the current price of 21.87.
What is the consensus rating for BEAM THERAPEUTICS INC (BEAM) stock?
The consensus rating for BEAM THERAPEUTICS INC (BEAM) is 86.3636 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover BEAM THERAPEUTICS INC (BEAM) stock?
The number of analysts covering BEAM THERAPEUTICS INC (BEAM) is 22.